{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:53:46Z","timestamp":1786982026223,"version":"build-2736575974"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,31]],"date-time":"2025-07-31T00:00:00Z","timestamp":1753920000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,7,31]],"date-time":"2025-07-31T00:00:00Z","timestamp":1753920000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"University of Bern"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Osteoporos"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>\n                      <jats:italic>Summary<\/jats:italic>\n                    <\/jats:title>\n                    <jats:p>\n                      This multicentre, retrospective case series analysed bone mineral density (BMD) changes in 26 patients who switched early from romosozumab (3\u201310\u00a0months) to antiresorptives. BMD gains over 12\u00a0months were similar to those in patients (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200999) completing the full 12-month course.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Romosozumab is typically administered for a duration of 12\u00a0months before transitioning to antiresorptive therapies. This study analysed the bone mineral density (BMD) changes of patients who were prematurely switched to an antiresorptive regimen.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This multicentre, retrospective case series investigated the BMD response to romosozumab administered for 3 to 10\u00a0months, followed by subsequent antiresorptive therapy, across four bone centres in Switzerland. BMD measurements at the lumbar spine, total hip and femoral neck were conducted at the initiation of romosozumab and again 12\u00a0months later. The study compared the BMD changes in patients who received short-term romosozumab with those in a cohort of patients who completed the full 12-month course.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Twenty-six patients (25 postmenopausal women and one man, median age 73\u00a0years [interquartile range: 65, 81]) were enrolled from February 2022 to December 2024. They received a median of six romosozumab injections (range: 3 to 10) and were prematurely switched to antiresorptives (14 to denosumab, 11 to zoledronate and one to alendronate) due to possible side effects or adverse events. Over 12\u00a0months, BMD increased by 13.5% [8.6, 16.6] at the lumbar spine, 2.9% [0.3, 7.3] at the total hip and 3.2% [0.4, 7.8] at the femoral neck, without significant differences compared with the cohort of 99 patients who received 12\u00a0months of romosozumab therapy. In both the short- and full-duration romosozumab treatment groups, significantly lower BMD responses were observed in patients who were pretreated with antiresorptives compared with those who were treatment na\u00efve.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In patients who underwent an early switch from romosozumab to antiresorptive therapy, BMD responses during the first year were similar to those in patients who completed the full 12-month romosozumab treatment. However, the subsequent changes in BMD, when all patients are receiving antiresorptive therapy, remain to be determined.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s11657-025-01598-1","type":"journal-article","created":{"date-parts":[[2025,7,31]],"date-time":"2025-07-31T13:32:27Z","timestamp":1753968747000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Early transition from short-term romosozumab to antiresorptive therapies: analysis of 26 cases"],"prefix":"10.1007","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8792-8199","authenticated-orcid":false,"given":"Judith","family":"Everts-Graber","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serge","family":"Ferrari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albrecht","family":"Popp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magaly","family":"Hars","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathias","family":"Wenger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sven","family":"Oser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ueli","family":"Studer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Steiner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans-Rudolf","family":"Ziswiler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gernot","family":"Schmid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Reichenbach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Lehmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Lamy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Gonzalez-Rodriguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,31]]},"reference":[{"issue":"1","key":"1598_CR1","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1002\/jbmr.173","volume":"26","author":"D Padhi","year":"2011","unstructured":"Padhi D, Jang G, Stouch B, Fang L, Posvarb E (2011) Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody. J Bone Miner Res 26(1):19\u201326. https:\/\/doi.org\/10.1002\/jbmr.173","journal-title":"J Bone Miner Res"},{"issue":"5","key":"1598_CR2","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1056\/NEJMoa1305224","volume":"370","author":"MR McClung","year":"2014","unstructured":"McClung MR, Grauer A, Boonen S et al (2014) Romosozumab in postmenopausal women with low bone mineral density. N Engl J Med 370(5):412\u201320. https:\/\/doi.org\/10.1056\/NEJMoa1305224","journal-title":"N Engl J Med"},{"issue":"9","key":"1598_CR3","doi-asserted-by":"publisher","first-page":"3183","DOI":"10.1210\/jc.2017-02163","volume":"103","author":"ME Lewiecki","year":"2018","unstructured":"Lewiecki ME, Blicharski E, Goemaere S et al (2018) A phase III randomized placebo-controlled trial to evaluate efficacy and safety of romosozumab in men with osteoporosis. J Clin Endocrinol Metab 103(9):3183\u20133193. https:\/\/doi.org\/10.1210\/jc.2017-02163","journal-title":"J Clin Endocrinol Metab"},{"issue":"16","key":"1598_CR4","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1056\/NEJMoa1607948","volume":"375","author":"F Cosman","year":"2016","unstructured":"Cosman F, Crittenden DB, Adachi JD et al (2016) Romosozumab Treatment in Postmenopausal Women with Osteoporosis. New England J Med 375(16):1532\u20131543. https:\/\/doi.org\/10.1056\/NEJMoa1607948","journal-title":"New England J Med"},{"issue":"15","key":"1598_CR5","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1056\/NEJMoa1708322","volume":"377","author":"KG Saag","year":"2017","unstructured":"Saag KG, Petersen J, Brandi ML et al (2017) Romosozumab or alendronate for fracture prevention in women with osteoporosis. N Engl J Med 377(15):1417\u20131427. https:\/\/doi.org\/10.1056\/NEJMoa1708322","journal-title":"N Engl J Med"},{"key":"1598_CR6","doi-asserted-by":"publisher","unstructured":"McClung MR, Brown JP, Diez-Perez A et al (2018), \u201cEffects of 24 months of treatment with romosozumab followed by 12 months of denosumab or placebo in postmenopausal women with low bone mineral density: a randomized, double-blind, phase 2, parallel group study. J Bone Mineral Rese 1397\u20131406. https:\/\/doi.org\/10.1002\/jbmr.3452.","DOI":"10.1002\/jbmr.3452"},{"key":"1598_CR7","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.bone.2017.11.003","volume":"107","author":"G Holdsworth","year":"2018","unstructured":"Holdsworth G, Greenslade K, Jose J et al (2018) Dampening of the bone formation response following repeat dosing with sclerostin antibody in mice is associated with up-regulation of Wnt antagonists. Bone 107:93\u2013103. https:\/\/doi.org\/10.1016\/j.bone.2017.11.003","journal-title":"Bone"},{"issue":"2","key":"1598_CR8","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1002\/jbmr.4193","volume":"36","author":"M Gerbaix","year":"2021","unstructured":"Gerbaix M, Ammann P, Ferrari S (2021) Mechanically driven counter-regulation of cortical bone formation in response to sclerostin-neutralizing antibodies. J Bone Miner Res 36(2):385\u2013399. https:\/\/doi.org\/10.1002\/jbmr.4193","journal-title":"J Bone Miner Res"},{"issue":"9","key":"1598_CR9","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1007\/s00198-024-07155-9","volume":"35","author":"J Everts-Graber","year":"2024","unstructured":"Everts-Graber J, Wenger M, Oser S et al (2024) The effect of romosozumab on bone mineral density depending on prior treatment: a prospective, multicentre cohort study in Switzerland. Osteoporos Int 35(9):1605\u20131613. https:\/\/doi.org\/10.1007\/s00198-024-07155-9","journal-title":"Osteoporos Int"},{"issue":"10102","key":"1598_CR10","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.1016\/S0140-6736(17)31613-6","volume":"390","author":"BL Langdahl","year":"2017","unstructured":"Langdahl BL, Libanati C, Crittenden C et al (2017) Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: a randomised, open-label, phase 3 trial. The Lancet 390(10102):1585\u20131594. https:\/\/doi.org\/10.1016\/S0140-6736(17)31613-6","journal-title":"The Lancet"},{"issue":"5","key":"1598_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbspin.2021.105219","volume":"88","author":"K Ebina","year":"2021","unstructured":"Ebina K, Tsuboi H, Nagayama Y et al (2021) Effects of prior osteoporosis treatment on 12-month treatment response of romosozumab in patients with postmenopausal osteoporosis. Joint Bone Spine 88(5):105219. https:\/\/doi.org\/10.1016\/j.jbspin.2021.105219","journal-title":"Joint Bone Spine"},{"issue":"6","key":"1598_CR12","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1007\/s00198-021-06261-2","volume":"33","author":"A Tominaga","year":"2022","unstructured":"Tominaga A, Wada K, Okazaki K et al (2022) \u201cImpact of the duration of previous osteoporosis treatment on the effect of romosozumab in patients with postmenopausal osteoporosis. Osteoporosis Internat 33(6):1265\u20131273. https:\/\/doi.org\/10.1007\/s00198-021-06261-2","journal-title":"Osteoporosis Internat"},{"issue":"3","key":"1598_CR13","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/j.jocd.2021.11.005","volume":"25","author":"F Poutoglidou","year":"2022","unstructured":"Poutoglidou F, Samoladas E, Raikos N, Kouvelas D (2022) Efficacy and safety of anti-sclerostin antibodies in the treatment of osteoporosis: a meta-analysis and systematic review. J Clin Densitom 25(3):401\u2013415. https:\/\/doi.org\/10.1016\/j.jocd.2021.11.005","journal-title":"J Clin Densitom"},{"issue":"1","key":"1598_CR14","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1002\/jbmr.4457","volume":"37","author":"EF Eriksen","year":"2022","unstructured":"Eriksen EF, Chapurlat R, Waite Boyce R et al (2022) Modeling-based bone formation after 2 months of romosozumab treatment: results from the FRAME clinical trial. J Bone Miner Res 37(1):36\u201340. https:\/\/doi.org\/10.1002\/jbmr.4457","journal-title":"J Bone Miner Res"},{"issue":"9","key":"1598_CR15","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1093\/jbmr\/zjae118","volume":"39","author":"P Chavassieux","year":"2024","unstructured":"Chavassieux P, Roux JP, Libanati C, Shi Y, Chapurlat R (2024) Bone-forming and antiresorptive effects of romosozumab in postmenopausal women with osteoporosis: bone histomorphometry and microcomputed tomography analysis after 2 and 12 months of treatment\u201d. J Bone Miner Res 39(9):1278\u20131283. https:\/\/doi.org\/10.1093\/jbmr\/zjae118","journal-title":"J Bone Miner Res"},{"issue":"6","key":"1598_CR16","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1093\/jbmr\/zjae055","volume":"39","author":"EF Eriksen","year":"2024","unstructured":"Eriksen EF, Waite Boyce R, Shi Y et al (2024) Reconstruction of remodeling units reveals positive effects after 2 and 12 months of romosozumab treatment. J Bone Miner Res 39(6):729\u2013736. https:\/\/doi.org\/10.1093\/jbmr\/zjae055","journal-title":"J Bone Miner Res"},{"issue":"7","key":"1598_CR17","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1002\/jbmr.3427","volume":"33","author":"F Cosman","year":"2018","unstructured":"Cosman F, Crittenden DB, Ferrari S et al (2018) FRAME study: the foundation effect of building bone with 1 year of romosozumab leads to continued lower fracture risk after transition to denosumab. J Bone Miner Res 33(7):1219\u20131226. https:\/\/doi.org\/10.1002\/jbmr.3427","journal-title":"J Bone Miner Res"},{"issue":"7","key":"1598_CR18","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1210\/clinem\/dgab193","volume":"106","author":"BL Langdahl","year":"2021","unstructured":"Langdahl BL, Hofbauer LC, Forfar JC (2021) Cardiovascular safety and sclerostin inhibition. J Clin Endocrinol Metab 106(7):1845\u20131853. https:\/\/doi.org\/10.1210\/clinem\/dgab193","journal-title":"J Clin Endocrinol Metab"}],"container-title":["Archives of Osteoporosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11657-025-01598-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11657-025-01598-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11657-025-01598-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T21:16:49Z","timestamp":1766524609000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11657-025-01598-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,31]]},"references-count":18,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1598"],"URL":"https:\/\/doi.org\/10.1007\/s11657-025-01598-1","relation":{},"ISSN":["1862-3514"],"issn-type":[{"value":"1862-3514","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,31]]},"assertion":[{"value":"9 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"SF: Amgen, UCB, Labatec, Gedeon Richter, Fresenius, Theramex, Agnovos. MW: UCB Pharma, Eli Lilly. SO: Amgen, Mylan. US: Janssen, Novartis, Pfizer, Sandoz, AbbVie, Amgen, Eli Lilly. CS: Abbvie. HRZ: Novartis, Jansen, Abbvie, Celgene. JEG, AP, GS, SR, TL, OL and EGR have nothing to declare. The authors declare no competing financial interests. The Swiss Osteoporosis Registry\u00a0is sponsored by public and industrial support (\n                      \n                      ). These sponsors had no role in the study design, the collection, analysis or interpretation of the data, the writing of the manuscript or the decision to submit the manuscript for publication. Publication of this article was not contingent upon approval by the study sponsors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}],"article-number":"106"}}